Pa­tients and in­ter­ested pub­lic

Risks and Be­ne­fits

Cur­rent treat­ment of AMD can be un­sat­is­fy­ing, due to fre­quency of in­jec­tions, which ne­ces­sit­ates reg­u­lar vis­its to the clin­ic. The Tar­get­AMD treat­ment aims at only one 1‑hour sur­gic­al ses­sion to deli­ver a safe and life-long solu­tion that re­sults in a com­fort­able and cost-ef­fi­cient cur­at­ive treat­ment.